Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 4.9% – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares dropped 4.9% during trading on Thursday . The company traded as low as $49.2850 and last traded at $49.2850. 330 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 2,757 shares. The stock had previously closed at $51.8050.

Analyst Ratings Changes

Several equities analysts have recently commented on ZLDPF shares. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

The firm has a market capitalization of $3.53 billion, a P/E ratio of 8.17 and a beta of 0.88. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $46.72 and its two-hundred day simple moving average is $48.40.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.